Hillstream BioPharma Announces Participation at the BioNJ’s 9th Annual BioPartnering Conference on May 8, 2019
May 1, 2019
Chester, N.J., May 01, 2019 – Hillstream BioPharma Inc. (“Hillstream”), a development-stage company advancing improved therapies for patients with cancer, today announced it intends to have a poster presentation at the BioNJ’s 9th Annual BioPartnering Conference at The Palace at Somerset Park, Somerset, N.J. 08873.
Event: BioNJ’s 9th Annual BioPartnering Conference
Date: Wednesday, May 8, 2019
Time: 9:00am-5:00pm EDT
Location: The Palace at Somerset Park, Somerset, NJ 08873
Hillstream’s Chief Executive Officer, Randy Milby, will provide an overview of the company’s business and scientific pipeline during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Hillstream will also be available for investor meetings outside the conference.
If you are an investor and would like to attend BioNJ’s 9th Annual BioPartnering Conference, please click on the following link (https://bionj.org/event/bionjs-9th-annual-biopartnering-conference ) to register. To book an individual appointment with Hillstream’s management, please contact Jennifer K. Zimmons, Ph.D., at +1 917.214.3514 or firstname.lastname@example.org.
About Hillstream BioPharma Inc.
Hillstream BioPharma Inc. (“Hillstream”) is a development-stage company advancing improved therapies for patients with cancer. Hillstream’s competitive advantage is to enhance the safety and efficacy of oncology therapies by encapsulating them in a polymeric injectable suspension comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows Hillstream to build a strong patent estate and seek FDA Orphan Drug Designation in specific indications.
Hillstream’s proprietary formulations of bortezomib, tumor necrosis factor – alpha and salinomycin are currently in preclinical development for cancers with significant unmet need. By taking advantage of the FDA’s 505(b)(2) regulatory pathway for bortezomib and paclitaxel, the Company could expedite the development process and bring these novel formulations to market to offer patients hope. For more information, please visit tharimmune.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
Jennifer K. Zimmons, Ph.D.
Zimmons International Communications
Tel: +1 917.214.3514
Source: Hillstream BioPharma Inc.